GALNT4 predicts survival in patients with ccRCC
As reported in the Journal of Urology, N-acetylgalactosaminyltransferase 4 (GALNT4) levels are decreased in tumor specimens from patients with clear cell renal cell carcinoma (ccRCC; n=104) compared to peritumoral specimens. Decreased expression of GALNT4 is associated with poor OS (OR=3.08) and RFS (OR=2.17). Further, GALNT4 is negatively correlated with tumor size, necrosis, and TNM stage.
PCA3 useful for early diagnosis of prostate cancer
Based on a meta-analysis reported in the Chinese Medical Journal, prostate cancer antigen 3 (PCA3) can be used for the early diagnosis of prostate cancer and to avoid unnecessary biopsies, with a sensitivity of 0.82, a specificity of 0.962, a positive likelihood ratio of 2.39, a negative likelihood ratio of 0.51, and a diagnostic odds ratio of 4.89.
High expression of MUC1 + HER3 is associated with favorable outcome in bladder cancer patients
As reported in BJU International, elevated co-expression of MUC1 + HER3 was associated with improved survival in patients with bladder cancer. MUC1 alone, or elevated MUC1 + non-elevated HER3, had no prognostic value. Moreover, MUC1 was not predictive of survival, tumor stage, or tumor grade.